ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2016

Sodium-glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin-metformin.

Stanley S Schwartz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.